BofA Securities Reiterates Buy Rating on Insmed (INSM); 'pullback overdone'
Tweet Send to a Friend
BofA Securities analyst Jason Zemansky reiterated a Buy rating and $214.00 price target on Insmed (NASDAQ: INSM) saying the Brinsupri ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
